Market Research Logo

Ipsen SA (IPN) - Financial and Strategic SWOT Analysis Review

Ipsen SA (IPN) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel medicines in cancer, neuroscience and rare diseases. It also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatology diseases. Ipsen sells its drugs through distributors and directly to hospitals in some countries. It has research and development (R&D) facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company provides products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

Ipsen SA Key Recent Developments

Feb 28,2019 Ipsen to Present New Data on Enhancement of Patient Care at the 16th European Neuroendocrine Tumor Society ENETS Annual Conference
Feb 26,2019 Ipsen to buy Clementia Pharmaceuticals in $1bn deal
Jan 11,2019 Ipsen demonstrates leadership position in neurotoxin research with strong presence at TOXINS 2019
Jan 03,2019 Cydan announces formation of Tiburio Therapeutics to develop treatments for Rare Neuroendocrine Tumors and Endocrine Diseases

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Ipsen SA - Key Facts
Ipsen SA - Key Employees
Ipsen SA - Key Employee Biographies
Ipsen SA - Major Products and Services
Ipsen SA - History
Ipsen SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Affiliate
Joint Venture
Section 2 – Company Analysis
Company Overview
Ipsen SA - Business Description
Business Segment: Consumer Healthcare
Overview
Performance
Business Segment: Specialty Care
Overview
Performance
Key Stats
Geographical Segment: Major Western European countries
Target Markets
Performance
Geographical Segment: North America
Performance
Geographical Segment: Other European Countries
Target Markets
Performance
Geographical Segment: Rest of the World
Target Markets
Performance
R&D Overview
Ipsen SA - Corporate Strategy
Ipsen SA - SWOT Analysis
SWOT Analysis - Overview
Ipsen SA - Strengths
Ipsen SA - Weaknesses
Ipsen SA - Opportunities
Ipsen SA - Threats
Ipsen SA - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Ipsen SA, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 28, 2019: Ipsen to Present New Data on Enhancement of Patient Care at the 16th European Neuroendocrine Tumor Society ENETS Annual Conference
Feb 26, 2019: Ipsen to buy Clementia Pharmaceuticals in $1bn deal
Jan 11, 2019: Ipsen demonstrates leadership position in neurotoxin research with strong presence at TOXINS 2019
Jan 03, 2019: Cydan announces formation of Tiburio Therapeutics to develop treatments for Rare Neuroendocrine Tumors and Endocrine Diseases
Dec 05, 2018: Exelixis and Ipsen Initiate Phase 3 Pivotal Trial COSMIC312 of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma
Nov 28, 2018: Ipsen France signs milestone cancer and employment charter at french Cancer National Institute
Nov 20, 2018: Ipsen and 3BP announce First Patient Dosed in Phase III study for firstinclass radionuclide IPN01087
Oct 31, 2018: Ipsen Group inaugurates new office in Singapore
Oct 25, 2018: Ipsen delivers strong sales growth of 20.2%1 for the third quarter of 2018 and confirms full year guidance
Oct 25, 2018: Ipsen Delivers Strong Sales Growth of 20.2%1 for the Third Quarter of 2018 and Confirms Full Year Guidance
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Ipsen SA, Key Facts
Ipsen SA, Key Employees
Ipsen SA, Key Employee Biographies
Ipsen SA, Major Products and Services
Ipsen SA, History
Ipsen SA, Subsidiaries
Ipsen SA, Affiliate
Ipsen SA, Joint Venture
Ipsen SA, Key Competitors
Ipsen SA, Ratios based on current share price
Ipsen SA, Annual Ratios
Ipsen SA, Annual Ratios (Cont...1)
Ipsen SA, Annual Ratios (Cont...2)
Ipsen SA, Interim Ratios
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Ipsen SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Ipsen SA, Performance Chart (2014 - 2018)
Ipsen SA, Ratio Charts
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report